Jim Cramer's 'Mad Money' Recap: Faith in the Market

Tickers in this article: AGN ALKS BMY EMC GE GME GOOG HAIN HD HDS NFLX NVO REGN SBUX TIVO TKR TSLA VMW WAG

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- You have to have faith if you're going to invest in the stock market, Jim Cramer told his "Mad Money" viewers Tuesday. Investors need to believe the companies they invest in will deliver on their promises. Fortunately, for some companies believing is not hard at all.

That's certainly the case with Regeneron , Cramer told viewers. This is one company that's repeatedly gotten it right despite analysts' predictions that the upside has already been "baked in" to the share price. Regeneron has deliverered a 5,900% return over the past nine years.

Allergan is another example of faith, Cramer continued. This stock fell last year from $115 to $85 on fears of generic drug competition. But six months ago Allergan's CEO appeared on Mad Money, telling viewers that the generic challenges were not a problem. Allergan's stock is up 34% since that appearance.

Cramer also offered a tip of the hat to Google for its acquisition of Nest, and Hain Celestial for its purchase of Tilda, makers of basmati rice. He was also bullish on Tesla Motors , a company that's still impossible to value but also one with a CEO who's impossible to ignore.

When can faith go awry? Cramer said he was wrong to trust Timken , which delivered the worst pre-announcement this year, and also GameStop , which neglected to mention its significant short-term challenges -- news that sent that stock down 19% in today's trading.

Executive Decision: Leonard Schleifer

For his "Executive Decision" segment, Cramer spoke with Leonard Schleifer, president and CEO of Regeneron, which today announced continued successes with its drug Eyelea as well as a promising pipeline that includes drugs for high cholesterol, arthritis and asthma among others.

Schleifer said that despite analysts' calls to the contrary, Eyelea has lots of room to grow thanks to favorable demographics, new geographies and, he hopes, new indications for the drug later in 2014. Regeneron is also making progress on its anti-cholesterol drug, for which the company hopes to file for approval early next year.

In addition, Regeneron is developing promising treatments for the epidemic of allergic diseases that are developing, as well as treatments for genetic ailments.